Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine
Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum...
Mirxes
Mirxes Secures China’s First Blood‑Test Approval for Gastric‑Cancer Screening
Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in‑vitro diagnostic (IVD) test, GASTROClear,...
Mirxes and NAGAWA Launch Free Gastric Cancer Screening Project in Japan
Singapore-based Mirxes Group (HKG: 2629) announced on July 23, 2025, that it has entered into...
Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits
Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing...
CBC Group’s R-Bridge Healthcare Fund Boosts Mirxes with $40M for Cancer Detection Expansion
CBC Group’s R-Bridge Healthcare Fund has made a significant investment of USD 40 million in...
Canhelp Genomics Partners with Mirxes to Expand Tumor Origin Testing in Southeast Asia
Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership...
Mirxes Holding Company Updates IPO Prospectus with 2024 Financials
Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit...
Cancer Diagnostics Firm Mirxes Aims for USD 100 Million in Hong Kong IPO
Mirxes, a Singapore-based company specializing in cancer diagnostics, has refiled a draft prospectus with the...
Mirxes Holding Company Receives FDA Breakthrough Device Designation for GASTROClea
Singapore-based RNA technology company, Mirxes Holding Company Ltd, which specializes in blood-based miRNA test kit...
Mirxes Holding Company Secures USD 50 Million in Series D Financing for RNA Technology
Mirxes Holding Company Ltd, a Singapore-headquartered RNA technology company specializing in blood-based miRNA test kit...